SI21169B - Nova uporaba peptidnega razreda spojine za zdravljenje alodinije ali drugih razliäśnih vrst kroniäśne ali fantomske boleäśine - Google Patents

Nova uporaba peptidnega razreda spojine za zdravljenje alodinije ali drugih razliäśnih vrst kroniäśne ali fantomske boleäśine Download PDF

Info

Publication number
SI21169B
SI21169B SI200220007A SI200220007A SI21169B SI 21169 B SI21169 B SI 21169B SI 200220007 A SI200220007 A SI 200220007A SI 200220007 A SI200220007 A SI 200220007A SI 21169 B SI21169 B SI 21169B
Authority
SI
Slovenia
Prior art keywords
compound
chronic
different types
phantom pain
formula
Prior art date
Application number
SI200220007A
Other languages
English (en)
Other versions
SI21169A (sl
Inventor
Norma Selve
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8176866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI21169(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Publication of SI21169A publication Critical patent/SI21169A/sl
Publication of SI21169B publication Critical patent/SI21169B/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Pričujoči izum zadeva novo uporabo spojin s formulo I za zdravljenje alodinije kot večjega in edinstvenega bolečinskega simptoma, neodvisnega od narave osnovne bolezni, ki pa je pogosto povezan z nevropatsko bolečino, ali drugih različnih vrst kronične ali fantomske bolečine.

Claims (7)

  1. Nova uporaba peptidnega razreda spojine za zdravljenje alodinije ali drugih različnih tipov kronične ali fantomske bolečine Patentni zahtevki 1. Uporaba spojine, ki ima formulo (I) H H i i (Formula I) Ar—CH2NHC—C—N—C—Qi Ul u o ch2 o I Q v kateri je Arfenil, ki je nesubstituiran ali substituiran z vsaj eno skupino halo, je Q nižji alkoksi, ki vsebuje 1-3 atome ogljika in Q-i je metil, ali njene farmacevtsko sprejemljive soli za pripravo farmacevtskega sestavka za zdravljenje fantomske bolečine ali šumenja v ušesu.
  2. 2. Uporaba po zahtevku 1, kjer je spojina ali njena farmacevtsko sprejemljiva sol v R-konfiguraciji.
  3. 3. Uporaba po zahtevku 1 ali 2, kjer je spojina v bistvu enantiočista.
  4. 4. Uporaba spojine po kateremkoli od zahtevkov od 1 do 3, kjer je Ar nesubstituiran fenil.
  5. 5. Uporaba spojine po kateremkoli od zahtevkov od 1 do 3, kjer je halo fluora.
  6. 6. Uporaba po zahtevku 1, kjer je spojina s formulo (I) (R)-2-acetamido-N-benzil-3-metoksipropionamid ali njegova farmacevtsko sprejemljiva sol. • · • · 2
  7. 7. Uporaba po zahtevku 6, kjer je spojina s formulo (I) (R)-2-acetamido-N-benzil-3-metoksipropionamid.
SI200220007A 2001-03-21 2002-03-19 Nova uporaba peptidnega razreda spojine za zdravljenje alodinije ali drugih razliäśnih vrst kroniäśne ali fantomske boleäśine SI21169B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01107026A EP1243263B1 (en) 2001-03-21 2001-03-21 Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
PCT/EP2002/003032 WO2002074297A1 (en) 2001-03-21 2002-03-19 Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain

Publications (2)

Publication Number Publication Date
SI21169A SI21169A (sl) 2003-10-31
SI21169B true SI21169B (sl) 2011-06-30

Family

ID=8176866

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200220007A SI21169B (sl) 2001-03-21 2002-03-19 Nova uporaba peptidnega razreda spojine za zdravljenje alodinije ali drugih razliäśnih vrst kroniäśne ali fantomske boleäśine

Country Status (26)

Country Link
US (3) US7875652B2 (sl)
EP (3) EP1243263B1 (sl)
JP (1) JP4154237B2 (sl)
KR (1) KR100557852B1 (sl)
CN (1) CN100522149C (sl)
AT (3) ATE228358T1 (sl)
AU (1) AU2002257680B2 (sl)
BR (1) BR0208141A (sl)
CA (1) CA2430470C (sl)
CZ (1) CZ20032798A3 (sl)
DE (2) DE60100055T2 (sl)
DK (1) DK1243263T3 (sl)
EA (1) EA007600B1 (sl)
ES (3) ES2185606T3 (sl)
HK (1) HK1048763B (sl)
HU (1) HUP0303983A3 (sl)
IL (3) IL155585A0 (sl)
MX (1) MXPA03006438A (sl)
NO (1) NO20033918L (sl)
PL (1) PL368408A1 (sl)
PT (1) PT1243263E (sl)
SI (1) SI21169B (sl)
SK (1) SK287714B6 (sl)
UA (1) UA73854C2 (sl)
WO (1) WO2002074297A1 (sl)
ZA (1) ZA200303319B (sl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1243262T3 (da) 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
EP1243263B1 (en) * 2001-03-21 2002-11-27 Schwarz Pharma Ag Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
EP1689378B1 (en) * 2003-12-02 2009-04-15 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
EP1537862A1 (en) * 2003-12-02 2005-06-08 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
KR20070007931A (ko) * 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604654A1 (en) 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EA014055B1 (ru) 2004-08-27 2010-08-30 Шварц Фарма Аг Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
EP1629839A1 (en) * 2004-08-27 2006-03-01 Schwarz Pharma Ag Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EA015566B1 (ru) 2005-01-28 2011-10-31 ЮСиБи ФАРМА ГМБХ Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
CA2631675A1 (en) * 2005-11-30 2007-06-21 The University Of North Carolina At Chapel Hill Identification of genetic polymorphic variants associated with somatosensory disorders and methods of using the same
US7902401B2 (en) 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
TWI397417B (zh) 2006-06-15 2013-06-01 Ucb Pharma Gmbh 具有協同抗驚厥功效之醫藥組成物
EP1920780A1 (en) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP2099444A4 (en) 2006-12-14 2012-11-07 Nps Pharma Inc USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
MD3310G2 (ro) * 2006-12-27 2008-02-29 Ион МЕРЕУЦЭ Metodă de tratament al durerilor fantome
EP2214657A1 (en) * 2007-10-23 2010-08-11 UCB Pharma GmbH Compounds for treating demyelination conditions
US8829033B2 (en) 2009-09-23 2014-09-09 The University Of North Carolina At Chapel Hill N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
BR112013013525A2 (pt) 2010-12-02 2016-10-18 Ucb Pharma Gmbh formulação de liberação controlada sólida de lacosamida para administração oral, composição farmacêutica sólida, e, método para a prevenção, alívio e/ou tratamento de uma doença do sistema nervoso central
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
GB201200525D0 (en) * 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
CN115175947A (zh) 2020-02-26 2022-10-11 Ａｇｃ株式会社 含氟聚合物、膜、膜的制造方法和有机光电子元件

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2937698A1 (de) 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4533657A (en) 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr) 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en) 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
JPH0680079B2 (ja) 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5654301A (en) 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5656267A (en) 1991-08-22 1997-08-12 Sagen; Jacqueline Implantable cells that alleviate chronic pain in humans
TW217417B (sl) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5536853A (en) 1994-04-11 1996-07-16 Chiron Corporation Opiate receptor ligands
MY113062A (en) 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5508266A (en) 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
WO1996011209A1 (en) 1994-10-05 1996-04-18 Chiroscience Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5780589A (en) 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5651301A (en) * 1994-12-13 1997-07-29 Unipat Aktiengessellschaft Hydrostatic piston machines
US5760038A (en) 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en) * 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
EP0840612A1 (en) 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
TW450807B (en) * 1995-09-15 2001-08-21 Pfizer Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents
US6114390A (en) 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614542A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
USRE41920E1 (en) 1996-07-24 2010-11-09 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6038324A (en) * 1997-02-21 2000-03-14 Ambourn; Paul R. Automotive surround sound circuit background of the invention
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
ATE320249T1 (de) 1997-07-08 2006-04-15 Ono Pharmaceutical Co Aminosäurederivate
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
AU7696098A (en) 1997-08-11 1999-03-01 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
US6509341B1 (en) 1997-10-31 2003-01-21 Abbott Laboratories Carboxylic acid derivatives, carrying amido side-chains; production and use as endothelin receptor antagonists
US6492553B1 (en) * 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
US6028102A (en) 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
GB9812683D0 (en) * 1998-06-12 1998-08-12 Smithkline Beecham Plc Novel compounds
CA2361402C (en) 1999-09-03 2009-05-12 Actelion Pharmaceuticals Ltd Bis-sulfonamides
SE0001373D0 (sv) 2000-04-13 2000-04-13 Karolinska Innovations Ab NPY Y1 receptor agonists and antagonists
US20020052418A1 (en) 2000-08-17 2002-05-02 Mitchell Shirvan Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
AU2001286763C1 (en) * 2000-08-25 2006-03-02 Research Corporation Technologies, Inc. New uses for amino acid anticonvulsants for treatment of pain
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DE60134337D1 (de) 2000-11-21 2008-07-17 Ucb Pharma Sa N-alkylierte gaba verbindungen, verfahren zu deren
DK1243262T3 (da) 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
EP1243263B1 (en) 2001-03-21 2002-11-27 Schwarz Pharma Ag Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
IL157093A0 (en) 2001-03-27 2004-02-08 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
WO2002088664A2 (en) 2001-04-26 2002-11-07 Bristol-Myers Squibb Company Control of compactability through crystallization
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
US7183259B2 (en) 2002-05-17 2007-02-27 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
AU2003264915A1 (en) 2002-08-05 2004-02-25 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
JP2006514110A (ja) 2002-11-11 2006-04-27 バイエル・ヘルスケア・アクチェンゲゼルシャフト Ｉｐ受容体アンタゴニストとしてのフェニルまたはヘテロアリールアミノアルカン誘導体
ATE384078T1 (de) 2002-11-18 2008-02-15 Bioprospecting Nb Inc Paralytisches peptide von der spitzmaus sowie dessen nutzung in der therapie von neuromuskulären krankheiten
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US6991764B2 (en) * 2002-12-13 2006-01-31 Dade Behring Inc. Method for replacing used reaction cuvettes in an automatic analyzer depending upon next scheduled assay
ES2280835T3 (es) 2002-12-19 2007-09-16 Pharmacia Corporation Formulacion no higroscopica que comprende un farmaco higroscopico.
CA2514574A1 (en) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
AU2004207010A1 (en) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
WO2004100871A2 (en) 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US7307669B2 (en) * 2003-06-24 2007-12-11 Broadcom Corporation System, method, and apparatus for displaying streams with dynamically changing formats
US7320675B2 (en) 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
EP1689378B1 (en) 2003-12-02 2009-04-15 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
EP1537862A1 (en) 2003-12-02 2005-06-08 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
EP1541138A1 (en) 2003-12-05 2005-06-15 Schwarz Pharma Ag Novel use of peptide compounds for treating status epilepticus or related conditions
US20060009384A1 (en) 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20050227961A1 (en) 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
KR20070007931A (ko) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1598428A1 (en) * 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
EP1604654A1 (en) 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EA014055B1 (ru) 2004-08-27 2010-08-30 Шварц Фарма Аг Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
EP1688137A1 (en) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 for add-on therapy of schizophrenia
US20060252749A1 (en) 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070043120A1 (en) 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070048372A1 (en) 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
TWI397417B (zh) * 2006-06-15 2013-06-01 Ucb Pharma Gmbh 具有協同抗驚厥功效之醫藥組成物
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
JP4355003B2 (ja) * 2007-03-08 2009-10-28 本田技研工業株式会社 内燃機関の制御装置
EP2214657A1 (en) * 2007-10-23 2010-08-11 UCB Pharma GmbH Compounds for treating demyelination conditions
CN101841984A (zh) * 2009-03-19 2010-09-22 鸿富锦精密工业（深圳）有限公司 电子装置及其按键组件

Also Published As

Publication number Publication date
HUP0303983A3 (en) 2012-01-30
DE60238524D1 (de) 2011-01-20
KR100557852B1 (ko) 2006-03-10
EP2201943A1 (en) 2010-06-30
PL368408A1 (en) 2005-03-21
ATE228358T1 (de) 2002-12-15
EP1243263A1 (en) 2002-09-25
EP1383487A1 (en) 2004-01-28
CZ20032798A3 (cs) 2007-06-20
SK12902003A3 (sk) 2004-06-08
SK287714B6 (en) 2011-07-06
IL155585A (en) 2010-12-30
ATE490766T1 (de) 2010-12-15
UA73854C2 (en) 2005-09-15
ES2185606T3 (es) 2003-05-01
DE60100055T2 (de) 2003-07-24
HK1048763B (zh) 2003-08-01
JP2004524337A (ja) 2004-08-12
ES2368317T3 (es) 2011-11-16
US7875652B2 (en) 2011-01-25
EA200300933A1 (ru) 2004-04-29
CA2430470C (en) 2008-11-04
ZA200303319B (en) 2003-07-08
CN1498104A (zh) 2004-05-19
EP2201943B1 (en) 2011-08-03
ES2354417T3 (es) 2011-03-14
PT1243263E (pt) 2003-03-31
NO20033918D0 (no) 2003-09-04
IL155585A0 (en) 2003-11-23
IL202688A0 (en) 2010-06-30
DE60100055D1 (de) 2003-01-09
CA2430470A1 (en) 2002-09-26
AU2002257680B2 (en) 2006-12-14
DK1243263T3 (da) 2003-03-17
US20110082211A1 (en) 2011-04-07
BR0208141A (pt) 2004-03-02
SI21169A (sl) 2003-10-31
CN100522149C (zh) 2009-08-05
US20100099770A1 (en) 2010-04-22
WO2002074297A1 (en) 2002-09-26
JP4154237B2 (ja) 2008-09-24
MXPA03006438A (es) 2004-05-24
NO20033918L (no) 2003-09-04
ATE518532T1 (de) 2011-08-15
US20040220077A1 (en) 2004-11-04
EP1243263B1 (en) 2002-11-27
KR20030076604A (ko) 2003-09-26
EP1383487B1 (en) 2010-12-08
HUP0303983A2 (hu) 2004-04-28
EA007600B1 (ru) 2006-12-29
HK1048763A1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
SI21169B (sl) Nova uporaba peptidnega razreda spojine za zdravljenje alodinije ali drugih razliäśnih vrst kroniäśne ali fantomske boleäśine
HK1094191A1 (en) Phenyl-carboxamide compounds useful for treating pain
BRPI9908319B1 (pt) composto amino cìclico, composição farmacêutica, medicamento contendo um composto amino cìclico ou um sal farmacologicamente aceitável do mesmo, e, uso de um composto amino cìclico ou um sal farmacologicamente aceitável do mesmo.
ATE369845T1 (de) Behandlung der nebenwirkungen von statinen
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
BRPI0412219A (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para regular a transdução de sinal método para tratamento ou prevenção de uma doença
DK0694545T3 (da) Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder
ATE268337T1 (de) C11-carbamate von antibakteriellen makroliden
WO2007125398A3 (en) : sulfonamide compounds as antagonists of the n-type calcium channel
DE60102171D1 (de) Ketolidantibiotika
EP0499544A3 (en) Use of tetrahydropiridin-derivatives as inhibitors of angiogenesis
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
UA88777C2 (en) Amide derivatives
NO20070617L (no) Kinoloninneholdende medisinske blandinger.
ATE340575T1 (de) Vorbeugung und behandlung von krankheiten in zusammenhang zu vaskularen funktionellen stoerungen un verbindung mit insulinresistenz
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
PT1167376E (pt) Antibioticos macrolidos
BRPI0417179A (pt) gentisato de amlodipina, método de preparar o mesmo e composição farmacêutica para tratamento de doenças cardiovasculares
BR0213633A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ou ativação aberrante de leucócitos
ATE511395T1 (de) Mittel zur behandlung von glomerulopathie
AU2058402A (en) Use of lipopeptides or lipoproteins for treating lung infections and lung tumours
BR0308911A (pt) Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto
SE0103272D0 (sv) Chemical compounds
EA200600271A1 (ru) Применение производных индазола для лечения невропатической боли
EA200400864A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ 2-(4-ЭТОКСИФЕНИЛ)-3-(4-МЕТАНСУЛЬФОНИЛФЕНИЛ)ПИРАЗОЛО[1,5-b]ПИРИДАЗИН В ФОРМЕ НАНОЧАСТИЦ

Legal Events

Date Code Title Description
IF Valid on the event date
OU02 Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims

Effective date: 20110511

SP73 Change of data on owner

Owner name: UCB PHARMA GMBH; DE

Effective date: 20110512

KO00 Lapse of patent

Effective date: 20130115